Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2024-06-06 Investor Presentation
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
本公司受邀參加第一金證券舉辦之法人說明會
Investor Presentation Classification · 90% confidence The document is a brief announcement about the company (1795 美時) participating in an investor conference hosted by First Securities. It provides details such as the date, time, and location of the investor presentation event. There is no detailed financial data or comprehensive report content included. The document is short (640 characters) and serves as a notification of an upcoming investor presentation rather than the presentation itself or a financial report. Therefore, it fits the category of Investor Presentation (IP).
2024-06-06 Chinese
本公司受邀參加國泰證券舉辦之法人說明會
Investor Presentation Classification · 90% confidence The document is a brief announcement about the company (1795 美時) participating in an investor presentation event organized by Cathay Securities. It includes details such as date, time, location, and a summary of the event. There is no detailed financial data or comprehensive report content. The document is short (641 characters) and serves as a notification of the event rather than the event materials or a full report. Therefore, it fits the category of Investor Presentation (IP) announcement rather than the presentation itself or a full report.
2024-06-06 Chinese
公告本公司董事會通過取得Teva Pharma(Thailand) Co., Ltd. 股權
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from a listed company (美時) regarding the board of directors' approval to acquire shares in Teva Pharma (Thailand) Co., Ltd. It details the transaction specifics such as the transaction date, parties involved, price, and other relevant information about the acquisition. The document is short (2095 characters) and focuses on a specific capital transaction rather than providing comprehensive financial data or a full report. There is no indication of financial statements or detailed analysis typical of annual or interim reports. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2024-06-06 Chinese
113年06月內部人持股轉讓(事前)
Director's Dealing Classification · 100% confidence The document contains detailed information about share transactions by company insiders, specifically managers transferring shares via trust arrangements. It lists names, share quantities, transfer methods, and dates. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document is short and focused solely on insider share transfers, with no financial statements or other report types referenced.
2024-06-06 Chinese
113年5月變更登記
Regulatory Filings Classification · 95% confidence The document is a brief disclosure from a listed company (美時) providing details about its capital stock, including authorized capital, paid-in capital, and changes in capital structure. It includes specific numeric data about shares and capital amounts but does not contain financial statements, management discussion, or detailed financial performance data. The document length is only 845 characters, indicating it is a short announcement rather than a full report. There is no indication of an annual or interim report, audit report, or earnings release. The content focuses on capital stock information, but it is not a detailed capital/financing update report; rather, it is a regulatory disclosure of capital stock status. Given the nature and length, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-24 Chinese
113年05月僑外投資持股
Major Shareholding Notification Classification · 95% confidence The document is a statistical table detailing the shareholding situation of overseas and mainland China investors, including changes in shareholdings before a shareholder meeting or ex-rights date. It provides specific numbers of shares held by different categories of investors and changes in those holdings. There is no indication of financial performance data, management discussion, audit information, or any report publication. The content is focused on shareholding notifications, specifically changes in significant share ownership levels. Therefore, the document fits the category of Major Shareholding Notification (MRQ). The document length is short and it is a direct report of shareholding data, not an announcement or a proxy statement.
2024-05-23 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.